Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib in Recurrent Hepatocellular Carcinoma After Liver Transplantation
NCT05103904Phase 2Terminated
- Sponsor
- Emory University
- Start
- Apr 2022
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenvatinib in hepatocellular carcinoma (HCC), sponsored by Emory University. Primary endpoint: Overall Response Rate up to 2 years. Started Apr 2022; status: terminated.
02
Drugs
lenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05103904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05103904.